Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: Summary of clinical trials

J. Wells Logan, Fernando R. Moya

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Introduction: Available literature suggests that the advantage of animal-derived surfactants over fi rst-generation synthetic agents derives from the presence of surface-active proteins and their phospholipid content. Here we summarize the results of clinical trials comparing animalderived surfactant preparations with other animal-derived surfactants and with both fi rst- and second-generation synthetic surfactants. Methods: Published clinical trials of comparisons of animal-derived surfactants were summarized and compared. Comparisons emphasized differences in (1) key surfactant components attributed with effi cacy and (2) differences in published outcomes. Results: For the most important outcomes, mortality and chronic lung disease, currently available natural surfactants are essentially similar in efficacy. When examining secondary outcomes (pneumothorax, ventilator weaning, and need for supplemental oxygen), it appears that both calfactant and poractant have an advantage over beractant. The weight of the evidence, especially for study design and secondary outcomes, favors the use of calfactant. However, the superiority of poractant over beractant, when the higher initial dose of poractant is used, strengthens the case for use of poractant as well. Conclusions: Clinical trials suggest that the higher surfactant protein-B content in calfactant, and perhaps the higher phospholipid content in poractant (at higher initial dose), are the factors that most likely confer the observed advantage over other surfactant preparations.

Original languageEnglish (US)
Pages (from-to)251-260
Number of pages10
JournalTherapeutics and Clinical Risk Management
Issue number1
StatePublished - 2009


  • Bronchopulmonary dysplasia
  • Chronic lung disease
  • Phospholipids
  • Respiratory distress syndrome
  • Surfactant
  • Surfactant proteins

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety


Dive into the research topics of 'Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: Summary of clinical trials'. Together they form a unique fingerprint.

Cite this